Allergan launches new product in Refresh line

Article

Refresh Optive Advanced Preservative-Free Lubricant Eye Drops from Allergan features the same formula as Refresh Optive Advanced but without a preservative.

 

Irvine, CA-Allergan, Inc. announced the launch of Refresh Optive Advanced Preservative-Free Lubricant Eye Drops. Refresh Optive Advanced Preservative-Free features the same formula that works on all three layers of the tear film to relieve dry eye symptoms as Refresh Optive Advanced but without the use of a preservative.

Refresh Optive Advanced Preservative-Free stabilizes the lipid layer to help reduce tear evaporation, hydrates the aqueous layer, and provides an advanced lubricating and protective shield to the mucin layer, while further protecting epithelial cells from hypertonic stress.

 

Some lipid-enhanced tears contain up to 2.0 uL of lipid per drop, which is up to 33 times more lipid than that found in a normal tear film. Refresh Optive Advanced Preservative-Free delivers <0.1uL of lipid per drop to stabilize the lipid layer and restore the lipid that has been lost while delivering an optimized amount for increased tolerability, according to the company.

Refresh Optive Advanced Preservative-Free is available in 30 count single-use vials and a preserved multi-dose formula. Both may be used in combination with dry eye prescription therapies and do not require shaking prior to use. 

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.